Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Phathom Pharmaceuticals, Inc. - Common Stock (NQ:PHAT)

7.559 -0.191 (-2.46%)
Streaming Delayed Price Updated: 11:35 AM EDT, Sep 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 224,912
Open 7.630
Bid (Size) 7.550 (1,600)
Ask (Size) 7.560 (500)
Prev. Close 7.750
Today's Range 7.535 - 7.763
52wk Range 7.590 - 18.31
Shares Outstanding 43,614,075
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire

Performance

YTD
-51.9%
-51.9%
1 Month
-18.3%
-18.3%
3 Month
-30.5%
-30.5%
6 Month
-32.2%
-32.2%
1 Year
-31.3%
-31.3%

More News

Read More
News headline image
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)
From Levi & Korsinsky, LLP
Via Business Wire
Phathom Pharmaceuticals (PHAT) Falls After Cutting 2026 Revenue Guidance Despite Q2 Beat ↗
Via Chartmill
Phathom Pharmaceuticals (NASDAQ:PHAT) Smashes Q1 Expectations, Nears Profitability Milestone ↗
Via Chartmill
Phathom Pharmaceuticals (NASDAQ:PHAT) Q4 2025 Earnings: Revenue Beat and Narrowed Losses Signal Path to Profitability ↗
Via Chartmill
News headline image
Phathom Pharmaceuticals Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom (PHAT) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom (PHAT) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharma Shows Sales Strength, Targets 2026 Profitability ↗
Via Benzinga
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
News headline image
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
From Phathom Pharmaceuticals
Via GlobeNewswire

Frequently Asked Questions

Is Phathom Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Phathom Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Phathom Pharmaceuticals, Inc. - Common Stock trade on?
Phathom Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Phathom Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Phathom Pharmaceuticals, Inc. - Common Stock is PHAT on the Nasdaq Stock Market
What is the current price of Phathom Pharmaceuticals, Inc. - Common Stock?
The current price of Phathom Pharmaceuticals, Inc. - Common Stock is 7.559
When was Phathom Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Phathom Pharmaceuticals, Inc. - Common Stock was at 09/18/26 11:35 AM ET
What is the market capitalization of Phathom Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Phathom Pharmaceuticals, Inc. - Common Stock is 329.70M
How many shares of Phathom Pharmaceuticals, Inc. - Common Stock are outstanding?
Phathom Pharmaceuticals, Inc. - Common Stock has 330M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.